Abstract
Thirty years have passed since Warren and Marshall's discovery of Helicobacter pylori (H. pylori). Since then, not only peptic ulcer diseases and chronic gastritis but also non-cardia gastric cancers have been recognized as diseases originating from H. pylori infection. Several combination therapies consisting of multiple antibiotics have been developed as first- or second-line regimens to eradicate H. pylori infection. Our extensive experience in the field of anti-H. pylori medicine suggests that clinicians should consider a possible role for unidentified, invisible pathogens to elucidate the pathogenesis and improve the treatment of refractory diseases of unknown etiology.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Amoxicillin / therapeutic use
-
Anti-Bacterial Agents / therapeutic use*
-
Clarithromycin / therapeutic use
-
Drug Therapy, Combination
-
Gastritis, Atrophic / drug therapy*
-
Gastritis, Atrophic / microbiology
-
Gene Expression Regulation, Bacterial / drug effects
-
Helicobacter Infections / drug therapy*
-
Helicobacter Infections / microbiology
-
Helicobacter pylori / drug effects
-
Helicobacter pylori / pathogenicity*
-
Helicobacter pylori / physiology
-
Humans
-
Japan
-
Lymphoma, B-Cell, Marginal Zone / drug therapy*
-
Lymphoma, B-Cell, Marginal Zone / microbiology
-
Peptic Ulcer / drug therapy*
-
Peptic Ulcer / microbiology
-
Proton Pump Inhibitors / therapeutic use
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / microbiology
-
Virulence
Substances
-
Anti-Bacterial Agents
-
Proton Pump Inhibitors
-
Amoxicillin
-
Clarithromycin